You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch.
You may also report side effects to Genentech at (888) 835-2555.
PERJETA® (pertuzumab) is indicated for use in combination with Herceptin® (trastuzumab) and chemotherapy for
PERJETA® (pertuzumab) is indicated for use in combination with Herceptin® (trastuzumab) and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
PERJETA is contraindicated in patients with known hypersensitivity to pertuzumab or to any of its excipients
Left Ventricular Dysfunction (LVD)
Infusion-Related Reactions
Hypersensitivity Reactions/Anaphylaxis
Neoadjuvant Treatment of Breast Cancer
Adjuvant Treatment of Breast Cancer
Metastatic Breast Cancer
You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Please see full Prescribing Information for additional Important Safety Information, including BOXED WARNINGS.